STAT Plus Chats
It’s October, which means it’s time for our biotech scorecard for the fourth quarter.
Each quarter, our biotech team sits down to outline the stock-moving events they’re keeping an eye on. This quarter, national biotech columnist Adam Feuerstein is looking at 13 market-moving events, including news from Amarin (AMRN), Karyopharm Therapeutics (KPTI), Vertex Pharmaceuticals (VRTX), and others. The first few weeks of October have already brought data from Sarepta Therapeutics (SRPT) showing its drug yielded improvements in muscle function for patients with rare limb-girdle disease; the purchase of Ra Pharmaceuticals (RARX) by UCB; and an Alexion (ALXN) acquisition of Achillion as the company expands research into rare, immune-related diseases.
In our subscriber-only chat, hosted last week by Adam, readers asked their burning questions on topics like these, and more.
Subscribe to STAT Plus to see a transcript of the conversation — and to access subscriber-only live chats like this on clinical trials, earnings readouts, and biopharma policy, for free in the future. Subscribers have exclusive access to ask questions and participate in these conversations with our reporters.